Trial Registered: Half-Dose vs Conventional-Dose Cetrorelix in ICSI Cycles

A clinical trial update involving cetrorelix was recorded on September 23, 2026. The study, registered under identifier NCT07836400, is titled "Half-dose vs Conventional-dose Cetrorelix in ICSI Cycles." Its current status is listed as not yet recruiting. No phase information was provided for this trial in the available record. The study appears designed to compare two dosing regimens of cetrorelix within the context of ICSI cycles, based solely on its registered title. No outcome data, enrollment figures, or results have been posted at this time. Because the trial has not yet begun recruiting participants, no conclusions can be drawn about safety, efficacy, or comparative performance between the two regimens described in the title. Readers should note that trial registration reflects only the planned scope of research and does not indicate any findings. Further updates may be issued once recruitment begins or results become available on the registry. For background on cetrorelix, including its approved regulatory status and general information, readers can consult the compound overview.